Navigation Links
FDA Approves Head Lice Treatment for Children and Adults
Date:1/18/2011

SILVER SPRING, Md., Jan. 18, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Natroba (spinosad) Topical Suspension 0.9% for the treatment of head lice infestation in patients ages 4 years and older.  

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Head lice are parasitic insects found on people's head, eyebrows, and eyelashes. They feed on human blood several times a day but are not known to cause disease. Head lice are spread mainly by direct head-to-head contact with a person who already has head lice.  Lice move by crawling and can easily travel from child to child because children play closely together and often in large groups.

"Natroba provides another option for the topical treatment of head lice infestations, which are especially prevalent in the pediatric population," said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research. "Head lice is a common problem among school children in the United States."

Natroba is a topical drug product and should be applied only to the child's scalp or hair.  The product should be used exactly as prescribed by a health care professional.

The safety and effectiveness of Natroba Topical Suspension 0.9 %, has been established in two multicenter, randomized, active-controlled studies. A total of 552 subjects received a 10-minute treatment with Natroba. If live lice were seen a week later, a second treatment was applied. The proportion of subjects who were lice-free fourteen days after the final treatment of Natroba was approximately 86 percent compared to 44 percent of the control group.  

Common adverse events reported include redness or irritation of the eyes and skin.

Safety in pediatric patients below the age of 4 years has not been established. Although Natroba is not approved for use in children younger than 4 years, it is especially important not to use in infants because the product contains benzyl alcohol.   Benzyl alcohol has been associated with serious adverse reactions, including death, when applied topically to the skin of children younger than 6 months.  

Natroba is manufactured for ParaPRO LLC of Carmel, Ind.

For more information:

Approved Drugs: Questions and Answers

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
2. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
3. FDA Approves New Dosage Strength for INTELENCE®
4. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
5. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
6. FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment
7. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
8. FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury
9. FDA Approves New Treatment Option for Late-Stage Breast Cancer
10. FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
11. FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... PUNE, India , January 16, 2017 ... titled, "Vital Signs Monitoring Devices Market by Type and End ... the global vital signs monitoring devices market size was worth ... million by 2022, growing at a CAGR of 5.8% from ... the leading regional market in global vital signs monitoring devices ...
(Date:1/16/2017)... and PUNE, India , January ... new report published by Allied Market Research, titled, "Sterilization ... Analysis and Industry Forecast, 2014-2022," the global sterilization technologies ... from $5,768 million in 2015, growing at a CAGR ... gas sterilization segment dominated the market in 2015, with ...
(Date:1/16/2017)... PORTLAND, Oregon and PUNE, India , January 16, ... Market Research, titled, "Antioxidants Market by Type - Global Opportunity Analysis and Industry ... and is expected to reach $4,531 million by 2022, registering a CAGR of ... accounted for more than one-third share of the global volume in 2015. ... ...
Breaking Medicine Technology:
(Date:1/16/2017)... Maryland (PRWEB) , ... January 16, 2017 , ... ... Thibodeau has been appointed Chief Executive Officer of the medical device company, effective ... Vixiar Chairman Robert Storey. “Kevin has a strong track record in medical ...
(Date:1/15/2017)... ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an ... new avenues for purchase. , The 2017 edition has wide jaws that will accommodate ... older boomers as well as diabetics. This handle is reinforced for extra strength when pressing ...
(Date:1/15/2017)... ... January 14, 2017 , ... Wondering where to go ... delivered straight to your door for a romantic, lobster feast in the comfort of ... for Valentine's Day. The dinners will be featured until February 15th, 2017. , ...
(Date:1/14/2017)... , ... January 13, 2017 , ... ... and Soul, incorporating a magnesium-rich Mediterranean diet may lower the risk of type ... Lounge notes that the many health and wellness benefits linked to a Mediterranean ...
(Date:1/13/2017)... ... ... The 18th European Congress: Perspectives in Lung Cancer will be held in ... is expertly designed to meet the educational needs of European oncology clinicians and researchers ... Dr. Giorgio V. Scagliotti, Professor of Oncology at the University of Torino, and organized ...
Breaking Medicine News(10 mins):